SCHEMBL29622013

SCHEMBL29622013

O=C1Cc2c(F)cccc2N1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.48
PDK2 Q15119 1/20 0.48
HTR5A P47898 1/20 0.46
DRD2 P14416 4/20 0.45
DRD4 P21917 3/20 0.45
DRD3 P35462 3/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
CHRM2 P08172 1/20 0.45
CYP3A4 P08684 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
ADRA2B P18089 1/20 0.45
DRD1 P21728 1/20 0.45
DRD5 P21918 1/20 0.45
HTR2A P28223 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261277 1.00 AHR (0.48) AHRPDK2HTR5ADRD2DRD4
SCHEMBL6321462 0.84 CCNB2 (0.48) AHRPDK2DRD2DRD4DRD3
SCHEMBL153534 0.84 CCNB2 (0.44) AHRPDK2DRD2DRD4DRD3
SCHEMBL156843 0.83 JAK2 (0.45) AHRPDK2DRD2DRD4DRD3
SCHEMBL29961206 0.82 SRD5A1 (0.57) AHRPDK2HTR5AHTR1AOPRK1
SCHEMBL3723532 0.82 SRD5A1 (0.57) AHRPDK2HTR5AHTR1AOPRK1
SCHEMBL27773795 0.82 TDP2 (0.40) AHRPDK2DRD2DRD4DRD3
SCHEMBL427457 0.79 MAPT (0.53) AHRPDK2HTR5ALMNACDK5
SCHEMBL22904170 0.77 TDP2 (0.52) GSK3BSRD5A1MEN1KMT2A
SCHEMBL2511443 0.76 TDP2 (0.53) AHRPDK2DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076632-A1 COMPOUNDS AND USES THEREOF FIBROCOR THERAPEUTICS INC. (CA) 2025-04-17 WO disclosed
WO-2025059429-A1 MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE BRISTOL-MYERS SQUIBB COMPANY (US) 2025-03-20 WO disclosed
EP-4514473-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS Celgene Corporation (US) 2025-03-05 EP disclosed
WO-2023212147-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS CELGENE CORPORATION (US) 2023-11-02 WO disclosed
CN-116802176-A Oxindoles and methods of use thereof 阿利戈斯治疗公司 2023-09-22 CN disclosed
EP-4240722-A1 OXINDOLES AND METHODS OF USE THEREOF Aligos Therapeutics, Inc. (US) 2023-09-13 EP disclosed
WO-2022099066-A1 OXINDOLES AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2022-05-12 WO disclosed